作者
Vijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, Amit Joshi, Nandini Menon, Atanu Bhattacharjee, Suyash Kulkarni, Suman Kumar Ankathi, Abhishek Mahajan, Nilesh Sable, Kavita Nawale, Arti Bhelekar, Sadaf Mukadam, Arun Chandrasekharan, Sudeep Das, Dilip Vallathol, Hollis D'Souza, Amit Kumar, Amit Agrawal, Satvik Khaddar, Narmadha Rathnasamy, Ramnath Shenoy, Lakhan Kashyap, Rahul Kumar Rai, George Abraham, Saswata Saha, Swaratika Majumdar, Naveen Karuvandan, Vijai Simha, Vasu Babu, Prahalad Elamarthi, Annu Rajpurohit, Kanteti Aditya Pavan Kumar, Anne Srikanth, Rahul Ravind, Shripad Banavali, Kumar Prabhash
发表日期
2020/9/1
期刊
The Lancet Global Health
卷号
8
期号
9
页码范围
e1213-e1222
出版商
Elsevier
简介
Background
Regimens for palliation in patients with head and neck cancer recommended by the US National Comprehensive Cancer Network (NCCN) have low applicability (less than 1–3%) in low-income and middle-income countries (LMICs) because of their cost. In a previous phase 2 study, patients with head and neck cancer who received metronomic chemotherapy had better outcomes when compared with those who received intravenous cisplatin, which is commonly used as the standard of care in LMICs. We aimed to do a phase 3 study to substantiate these findings.
Methods
We did an open-label, parallel-group, non-inferiority, randomised, phase 3 trial at the Department of Medical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India. We enrolled adult patients (aged 18–70 years) who planned to receive palliative systemic treatment for relapsed, recurrent, or newly diagnosed …
学术搜索中的文章
V Patil, V Noronha, SB Dhumal, A Joshi, N Menon… - The Lancet Global Health, 2020